A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
- Registration Number
- NCT06407934
- Lead Sponsor
- Sanofi
- Brief Summary
This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 years and older diagnosed with moderate-to-severe atopic dermatitis (AD).
The main objective of this study is to evaluate if those participants who received amlitelimab dose 1 in the parent studies (EFC17559 \[COAST-1\], EFC17560 \[COAST 2\], EFC17561 \[SHORE\]) and were responders can maintain their response either remaining at dose 1 or switching to dose 2 of amlitelimab compared to treatment withdrawal.
Study details include:
The study duration will be up to 68 weeks including a 52-week randomized double-blind period, and a 16-week safety follow-up for participants not entering the LTS17367 (RIVER-AD).
The study duration will be up to 52 weeks for participants entering the LTS17367 \[RIVER-AD\] study at the Week 52 visit of EFC17600 (ESTUARY).
The total treatment duration will be up to 52 weeks. The total number of visits will be up to 15 visits (or 14 visits for those entering LTS17367 \[RIVER-AD\] study).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 961
- Participants must be at least 12 years of age inclusive, at the time the informed consent is signed.
- Must have participated, received study treatment without permanent investigational medicinal product (IMP) discontinuation, and adequately completed the assessments required for the treatment period in one of the three 24-week parent studies EFC17559 (COAST-1), EFC17560 (COAST-2) or EFC17561 (SHORE) for moderate-to-severe AD.
- Able and willing to comply with requested study visit and procedures.
- Body weight must be ≥ 25 kg.
Participants are excluded from the study if any of the following criteria apply:
- Developed a medical condition that would preclude participation as described in Permanent Discontinuation of EFC17559 (COAST-1)/EFC17560 (COAST-2)/EFC17561 (SHORE) clinical trial protocols.
- Having received any prohibited medication or procedure for AD that resulted in IMP discontinuation in the parent study EFC17559 (COAST-1), EFC17560 (COAST-2) or EFC17561 (SHORE).
- Participants who, during their participation in the parent study EFC17559 (COAST-1) /EFC17560 (COAST-2)/EFC17561 (SHORE), developed an adverse event (AE) or a serious adverse event (SAE) deemed related to amlitelimab, which in the opinion of the Investigator could indicate that continued treatment with amlitelimab may present an unreasonable risk for the participant.
- Participants who have had IMP permanently discontinued for any reason before or at the time of the planned first dose in the EFC17600 (ESTUARY) study.
- Conditions in the parent study EFC17559 (COAST-1)/EFC17560 (COAST-2)/EFC17561 (SHORE) that led to Investigator - or Sponsor-initiated withdrawal of participant from the study (eg, non-compliance, inability to complete study assessments, etc.).
- Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Amlitelimab dose 1 Amlitelimab Subcutaneous injection as per protocol Amlitelimab dose 2 Amlitelimab Subcutaneous injection as per protocol Placebo Placebo Subcutaneous injection as per protocol
- Primary Outcome Measures
Name Time Method Proportion of participants who maintain treatment response at Week 48 of ESTUARY. Week 48 Maintenance of clinical response is defined as having validated Investigator Global Assessment scale for atopic dermatitis (vIGA-AD) 0 (clear) or 1 (almost clear) and/or 75% reduction in Eczema Area and Severity Index (EASI) compared to parent study baseline EASI (EASI-75). The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe). The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.
- Secondary Outcome Measures
Name Time Method Non-responders from parent studies: Proportion of participants who are vIGA-AD 0 (clear) or 1 (almost clear) with presence of only barely perceptible erythema (no induration/papulation, no lichenification, no oozing or crusting) Up to Week 48 The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).
Non-responders from parent studies: Proportion of participants with ≥ 4 points reduction in weekly average of daily PP-NRS from parent study baseline Up to Week 48 The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.
Non-responders from parent studies: Percent change in weekly average of daily PP-NRS from parent study baseline Parent study baseline to Week 48 The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.
Non-responders from parent studies: Absolute change in weekly average of daily PP-NRS from parent study baseline Parent study baseline to Week 48 The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.
Non-responders from parent studies: Absolute change in weekly average of daily SD-NRS from parent study baseline Parent study baseline to Week 48 The SD-NRS is a single item 0-10 numeric rating scale assessing sleep disturbance associated with AD with 0 = no sleep loss and 10 = did not sleep at all.
Non-responders from parent studies: Proportion of participants with ≥3 points reduction in weekly average of daily SD-NRS from parent study baseline Up to Week 48 The SD-NRS is a single item 0-10 numeric rating scale assessing sleep disturbance associated with AD with 0 = no sleep loss and 10 = did not sleep at all.
Non-responders from parent studies: Proportion of participants with ≥ 4 points reduction in weekly average of daily SP-NRS from parent study baseline [ Up to Week 48 The SP-NRS is a single item 0-10 numeric rating scale assessing skin pain associated with AD with 0 = no pain and 10 = worst possible pain imaginable.
Non-responders from parent studies: Absolute change in weekly average of daily SP-NRS from parent study baseline Parent study baseline to Week 48 The SP-NRS is a single item 0-10 numeric rating scale assessing skin pain associated with AD with 0 = no pain and 10 = worst possible pain imaginable.
Non-responders from parent studies: Proportion of participants with a reduction in CDLQI ≥6 among participants aged ≥12 to <16 years old and with CDLQI ≥6 at parent study baseline Up to Week 48 The DLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in adult patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.
Non-responders from parent studies: Change in CDLQI in participants with age ≥12 to <16 years old Parent study baseline to Week 48 The DLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in adult patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.
Non-responders from parent studies: Change in DLQI in participants with age ≥16 years among the participants with DLQI ≥4 at parent study baseline Parent study baseline to Week 48 The DLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in adult patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.
Non-responders from parent studies: Proportion of participants with ≥ 4 points reduction in DLQI from parent study baseline among the participants with DLQI ≥4 at parent study baseline Up to Week 48 The DLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in adult patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.
Non-responders from parent studies: Proportion of participants with HADS-D <8 among the participants who had HADS-D ≥8 at parent study baseline Up to Week 48 The HADS is 14-item questionnaire with two subscales: anxiety \& depression. Each subscale (anxiety \& depression) ranges 0-21. The total HADS score ranges 0-42 with higher score indicating a poorer state.
Non-responders from parent studies: Proportion of participants with HADS-A <8 among the participants who had HADS-A ≥8 at parent study baseline Up to Week 48 The HADS is 14-item questionnaire with two subscales: anxiety \& depression. Each subscale (anxiety \& depression) ranges 0-21. The total HADS score ranges 0-42 with higher score indicating a poorer state.
All participants: Percentage of participants who experienced Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and/or Treatment-Emergent Adverse Events of Special Interest (AESI) Up to week 68 All participants: Serum amlitelimab concentrations measured at prespecified timepoints Up to Week 68 All participants: Incidence of antidrug antibodies (ADAs) of amlitelimab Up to Week 68 Responders from parent studies: Time to the first event of loss of EASI-75 response among the participants who were EASI-75 responders at baseline of ESTUARY Up to Week 48 The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75 is 75% reduction from baseline in EASI score.
Responders from parent studies: Time to the first event of loss of EASI-50 response among the participants who were EASI-50 responders at baseline of ESTUARY Up to Week 48 The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-50 is 50% reduction from baseline in EASI score.
Responders from parent studies: Time to the first event of loss of EASI-90 response among the participants who were EASI-90 responders at baseline of ESTUARY Up to Week 48 The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-90 is 90% reduction from baseline in EASI score.
Responders from parent studies: Time to the first event of loss of EASI-100 among participants who were EASI-100 at baseline of ESTUARY Up to Week 48 The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-100 is 100% reduction from baseline in EASI score.
Responders from parent studies: Proportion of participants with vIGA-AD 0 (clear) or 1 (almost clear) Up to Week 48 The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).
Responders from parent studies: Proportion of participants who are vIGA-AD 0 (clear) or 1 (almost clear) with presence of only barely perceptible erythema (no induration/papulation, no lichenification, no oozing or crusting) Up to Week 48 The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).
Responders from parent studies: Time to first event of vIGA-AD ≥3 (moderate or severe) among those participants who were vIGA-AD 0 (clear) or 1 (almost clear) at baseline of ESTUARY Up to Week 48 The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).
Responders from parent studies: Time to first event of vIGA-AD ≥3 (moderate or severe) among those participants who were vIGA-AD 0 (clear) at baseline of ESTUARY Up to Week 48 The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).
Responders from parent studies: Proportion of participants who have an increase of ≥2 points in vIGA-AD from ESTUARY baseline among the participants who were vIGA-AD 0 (clear) or 1 (almost clear) at baseline of ESTUARY Up to Week 48 The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).
Responders from parent studies: Proportion of participants who have an increase of ≥2 points in vIGA-AD from ESTUARY baseline among the participants who were vIGA-AD 3 (moderate) at baseline of parent study Up to Week 48 The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).
Responders from parent studies: Proportion of participants who have an increase of ≥2 points in vIGA-AD from ESTUARY baseline among the participants who were vIGA-AD 4 (severe) at baseline of parent study Up to Week 48 The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).
Responders from parent studies: Proportion of participants who maintained POEM ≥4 among the participants with reduction in POEM ≥4 at baseline of ESTUARY Up to Week 48 The Patient Oriented Eczema Measure (POEM) is a 7-item self-assessment questionnaire that assesses disease symptoms on a 5-point scale; 0 (no days) to 4 (every day in the last week). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (very severe). Higher scores indicated more severe disease and poor quality of life.
Responders from parent studies: Change in POEM from parent study baseline Parent study baseline to Week 48 The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms on a 5-point scale; 0 (no days) to 4 (every day in the last week). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (very severe). Higher scores indicated more severe disease and poor quality of life.
Responders from parent studies: Proportion of participants with a reduction in Children's Dermatology Life Quality Index (CDLQI) ≥6 among participants aged ≥12 to <16 years old and with CDLQI baseline ≥6 Up to Week 48 The CDLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in children aged 4-\<16 years. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.
Responders from parent studies: Change in CDLQI in participants with age ≥12 to <16 years old Parent study baseline to Week 48 The CDLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in children aged 4-\<16 years. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.
Responders from parent studies: Change in Dermatology Life Quality Index (DLQI) in participants with age ≥16 years among the participants with DLQI ≥4 at parent study baseline Parent study baseline to Week 48 The DLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in adult patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.
Responders from parent studies: Proportion of participants with ≥ 4 points reduction in DLQI from parent study baseline among the participants with DLQI ≥4 at parent study baseline Up to Week 48 The DLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in adult patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.
Responders from parent studies: Proportion of participants with HADS-D <8 among the participants who had HADS-D ≥8 at parent study baseline Up to Week 48 The Hospital Anxiety Depression Scale-Depression (HADS) ranges 0-21 with higher score indicating a poorer state.
Responders from parent studies: Proportion of participants with HADS-A <8 among the participants who had HADS-A ≥8 at parent study baseline Up to Week 48 The Hospital Anxiety Depression Scale-Anxiety (HADS-A) ranges 0-21 with higher score indicating a poorer state.
Responders from parent studies: Proportion of participants requiring rescue medication during the study up to Week 48 of ESTUARY Up to Week 48 Responders from parent studies: Time to first rescue medication initiation Up to Week 48 Non-responders from parent studies: Percent change in EASI from parent study baseline Parent study baseline to Week 48 The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.
Non-responders from parent studies: Proportion of participants with EASI-75 Up to Week 48 The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75 is 75% reduction from baseline in EASI score.
Non-responders from parent studies: Proportion of participants who continue to be EASI-50 among the participants who met EASI-50 at baseline of ESTUARY Up to Week 48 The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-50 is 50% reduction from baseline in EASI score.
Non-responders from parent studies: Proportion of participants with EASI-50 Up to Week 48 The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-50 is 50% reduction from baseline in EASI score.
Non-responders from parent studies: Proportion of participants with EASI-90 Up to Week 48 The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-90 is 90% reduction from baseline in EASI score.
Non-responders from parent studies: Proportion of participants with EASI-100 Up to Week 48 The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-100 is 100% reduction from baseline in EASI score.
Non-responders from parent studies: Proportion of participants with vIGA-AD 0 (clear) or 1 (almost clear) Up to Week 48 The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).
Responders from parent studies: Proportion of participants who continue to be EASI-75 among the participants who met EASI-75 at baseline of ESTUARY Up to Week 48 The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75 is 75% reduction from baseline in EASI score.
Responders from parent studies: Proportion of participants who continue to be vIGA-AD 0 (clear) or 1 (almost clear) among participants who met vIGA-AD 0 (clear) or 1 (almost clear) at baseline of ESTUARY Up to Week 48 The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).
Responders from parent studies: Proportion of participants who continue to be vIGA-AD 0 or 1 with presence of only barely perceptible erythema among those who are vIGA-AD 0 or 1 with presence of only barely perceptible erythema at baseline of ESTUARY Up to Week 48 The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear), 1 (almost clear) to 4 (severe). Barely perceptible erythema with no induration/papulation, no lichenification, no oozing or crusting.
Responders from parent studies: Proportion of participants who maintained weekly average of daily PP-NRS reduction of ≥4 among the participants with weekly average of daily PP-NRS reduction of ≥ 4 at baseline of ESTUARY Up to Week 48 The Peak Pruritus-Numerical Rating Scale (PP-NRS) is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.
Proportion of participants who maintain treatment response in ESTUARY Up to Week 44 Maintenance of treatment response is defined as having vIGA-AD 0 (clear) or 1 (almost clear) and/or 75% reduction in EASI compared to parent study baseline EASI. The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.
Responders from parent studies: Percent change in EASI from parent study baseline Parent study baseline to Week 48 The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.
Responders from parent studies: Proportion of participants with EASI-75 Up to Week 48 The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75 is 75% reduction from baseline in EASI score.
Responders from parent studies: Proportion of participants who continue to be EASI-50 among the participants who met EASI-50 at baseline of ESTUARY Up to Week 48 The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-50 is 50% reduction from baseline in EASI score.
Responders from parent studies: Proportion of participants with EASI-50 Up to Week 48 The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-50 is 50% reduction from baseline in EASI score.
Responders from parent studies: Proportion of participants who continue to be EASI-90 among the participants who met EASI-90 at baseline of ESTUARY Up to Week 48 The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-90 is 90% reduction from baseline in EASI score.
Responders from parent studies: Proportion of participants with EASI-90 Up to Week 48 The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-90 is 90% reduction from baseline in EASI score.
Responders from parent studies: Proportion of participants who continue to be EASI-100 among the participants who met EASI-100 at baseline of ESTUARY Up to Week 48 The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-100 is 100% reduction from baseline in EASI score.
Responders from parent studies: Proportion of participants with EASI-100 Up to Week 48 The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-100 is 100% reduction from baseline in EASI score.
Responders from parent studies: Proportion of participants with vIGA-AD 0 (clear) or 1 (almost clear) and/or EASI-75 among the participants who were vIGA-AD 0 (clear) or 1 (almost clear) and/or EASI-75 at baseline of ESTUARY Up to Week 48 The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe). The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75 is 75% reduction from baseline in EASI score.
Responders from parent studies: Proportion of participants with ≥ 4 points reduction in weekly average of daily PP-NRS from parent study baseline Up to Week 48 The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.
Responders from parent studies: Percent change in weekly average of daily PP-NRS from parent study baseline Parent study baseline to Week 48 The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.
Responders from parent studies: Absolute change in weekly average of daily PP-NRS from parent study baseline Parent study baseline to Week 48 The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.
Responders from parent studies: Proportion of participants who maintained PP-NRS 0 or 1 among the participants who were PP-NRS 0 or 1 at baseline of ESTUARY Up to Week 48 The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.
Responders from parent studies: Proportion of participants who maintained vIGA-AD 0 or 1 and/or EASI-75 and weekly average of daily (WAD) PP-NRS reduction >4 among those who were vIGA-AD 0 or 1 and/or EASI-75 and WAD PP-NRS reduction >4 at BL of ESTUARY Up to Week 48 The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear), 1 (almost clear) to 4 (severe). The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75 is 75% reduction from baseline in EASI score. The Peak Pruritus-Numerical Rating Scale (PP-NRS) is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable. BL=baseline.
Responders from parent studies: Absolute change in weekly average of daily SD-NRS from parent study baseline Parent study baseline to Week 48 The Sleep Disturbance-Numerical Rating Scale (SD-NRS) is a single item 0-10 numeric rating scale assessing sleep disturbance associated with AD with 0 = no sleep loss and 10 = did not sleep at all.
Responders from parent studies: Proportion of participants who maintained weekly average of daily SD-NRS reduction of ≥ 3 among the participants with weekly average of daily SD-NRS reduction of ≥3 at baseline of ESTUARY Up to Week 48 The SD-NRS is a single item 0-10 numeric rating scale assessing sleep disturbance associated with AD with 0 = no sleep loss and 10 = did not sleep at all.
Responders from parent studies: Proportion of participants with ≥3 points reduction in weekly average of daily SD-NRS from parent study baseline Up to Week 48 The SD-NRS is a single item 0-10 numeric rating scale assessing sleep disturbance associated with AD with 0 = no sleep loss and 10 = did not sleep at all.
Responders from parent studies: Proportion of participants with ≥ 4 points reduction in weekly average of daily SP-NRS from parent study baseline Up to Week 48 The Skin Pain-Numerical Rating Scale (SP-NRS) is a single item 0-10 numeric rating scale assessing skin pain associated with AD with 0 = no pain and 10 = worst possible pain imaginable.
Responders from parent studies: Proportion of participants who maintained weekly average of daily SP-NRS reduction of ≥ 4 among the participants with weekly average of daily SP-NRS reduction of ≥4 at ESTUARY baseline Up to Week 48 The SP-NRS is a single item 0-10 numeric rating scale assessing skin pain associated with AD with 0 = no pain and 10 = worst possible pain imaginable.
Responders from parent studies: Absolute change in weekly average of daily SP-NRS from parent study baseline Parent study baseline to Week 48 The SP-NRS is a single item 0-10 numeric rating scale assessing skin pain associated with AD with 0 = no pain and 10 = worst possible pain imaginable.
Responders from parent studies: Proportion of participants who maintained SCORAD ≥ 8.7 among participants with reduction in SCORAD ≥ 8.7 at baseline of ESTUARY Up to Week 48 The Scoring Atopic Dermatitis (SCORAD) index is a clinical tool to evaluate the extent and severity of AD. Total score ranges from 0 (absent disease) to 103 (severe disease).
Responders from parent studies: Percent change in SCORAD index from parent study baseline Parent study baseline to Week 48 The SCORAD index is a clinical tool to evaluate the extent and severity of AD. Total score ranges from 0 (absent disease) to 103 (severe disease).
Responders from parent studies: Absolute change in SCORAD index from parent study baseline Parent study baseline to Week 48 The SCORAD index is a clinical tool to evaluate the extent and severity of AD. Total score ranges from 0 (absent disease) to 103 (severe disease).
Responders from parent studies: Change in percent Body Surface Area (BSA) affected by AD from parent study baseline Parent study baseline to Week 48
Trial Locations
- Locations (310)
Investigational Site Number : 1560041
🇨🇳Shenyang, China
Investigational Site Number : 1560026
🇨🇳Shenyang, China
Investigational Site Number : 1560064
🇨🇳Shenzhen, China
Investigational Site Number : 1560023
🇨🇳Wenzhou, China
Cahaba Dermatology & Skin Health Center- Site Number : 8401066
🇺🇸Birmingham, Alabama, United States
Center for Dermatology and Plastic Surgery- Site Number : 8401119
🇺🇸Scottsdale, Arizona, United States
Scottsdale Clinical Trials- Site Number : 8401149
🇺🇸Scottsdale, Arizona, United States
Eclipse Clinical Research- Site Number : 8401158
🇺🇸Tucson, Arizona, United States
Johnson Dermatology- Site Number : 8401076
🇺🇸Fort Smith, Arkansas, United States
Encino Research Center- Site Number : 8401042
🇺🇸Encino, California, United States
First OC Dermatology- Site Number : 8401025
🇺🇸Fountain Valley, California, United States
Center for Dermatology Clinical Research- Site Number : 8401018
🇺🇸Fremont, California, United States
Marvel Clinical Research- Site Number : 8401102
🇺🇸Huntington Beach, California, United States
Sunwise Clinical Research- Site Number : 8401022
🇺🇸Lafayette, California, United States
Torrance Clinical Research- Site Number : 8401027
🇺🇸Lomita, California, United States
Rophe Adult & Pediatric Medicine- Site Number : 8401289
🇺🇸Union City, Georgia, United States
Dermatology Research Associates - Los Angeles- Site Number : 8401092
🇺🇸Los Angeles, California, United States
LA Universal Research Center- Site Number : 8401064
🇺🇸Los Angeles, California, United States
Northridge Clinical Trials - Northridge- Site Number : 8401080
🇺🇸Northridge, California, United States
Cura Clinical Research - Oxnard- Site Number : 8401142
🇺🇸Oxnard, California, United States
Southern California Dermatology- Site Number : 8401043
🇺🇸Santa Ana, California, United States
Clinical Science Institute- Site Number : 8401028
🇺🇸Santa Monica, California, United States
University of Connecticut Health Center- Site Number : 8401115
🇺🇸Farmington, Connecticut, United States
Pediatric Skin Research- Site Number : 8401198
🇺🇸Coral Gables, Florida, United States
St Jude Clinical Research- Site Number : 8401287
🇺🇸Doral, Florida, United States
Direct Helpers Research Center- Site Number : 8401056
🇺🇸Hialeah, Florida, United States
Encore Medical Research - Hollywood- Site Number : 8401030
🇺🇸Hollywood, Florida, United States
Savin Medical Group - Miami Lakes- Site Number : 8401085
🇺🇸Miami Lakes, Florida, United States
Clever Medical Research- Site Number : 8401160
🇺🇸Miami, Florida, United States
Florida International Research Center- Site Number : 8401091
🇺🇸Miami, Florida, United States
Miami Dermatology and Laser Research - Miami - Southwest 87th Avenue- Site Number : 8401086
🇺🇸Miami, Florida, United States
Nuline Clinical Trial Center- Site Number : 8401161
🇺🇸Pompano Beach, Florida, United States
Global Clinical Professionals (GCP)- Site Number : 8401045
🇺🇸Saint Petersburg, Florida, United States
Clinical Research Trials of Florida- Site Number : 8401023
🇺🇸Tampa, Florida, United States
Cleaver Medical Group Dermatology- Site Number : 8401139
🇺🇸Cumming, Georgia, United States
Cleaver Medical Group- Site Number : 8401138
🇺🇸Dawsonville, Georgia, United States
First Georgia Physician Group- Site Number : 8401190
🇺🇸Fayetteville, Georgia, United States
Skin Care Physicians of Georgia - Macon- Site Number : 8401034
🇺🇸Macon, Georgia, United States
Javara Research - Thomasville- Site Number : 8401189
🇺🇸Thomasville, Georgia, United States
NorthShore University HealthSystem - Skokie- Site Number : 8401038
🇺🇸Skokie, Illinois, United States
Dawes Fretzin Clinical Research- Site Number : 8401015
🇺🇸Indianapolis, Indiana, United States
Skin Sciences- Site Number : 8401039
🇺🇸Louisville, Kentucky, United States
MedPharmics - Covington- Site Number : 8401137
🇺🇸Covington, Louisiana, United States
Velocity Clinical Research - Lafayette- Site Number : 8401152
🇺🇸Lafayette, Louisiana, United States
Beth Israel Deaconess Medical Center - Fort Myers- Site Number : 8401286
🇺🇸Boston, Massachusetts, United States
Metro Boston Clinical Partners- Site Number : 8401128
🇺🇸Needham, Massachusetts, United States
Revival Research Institute - Dearborn- Site Number : 8401012
🇺🇸Dearborn, Michigan, United States
Henry Ford Hospital- Site Number : 8401044
🇺🇸Detroit, Michigan, United States
Oakland Medical Center- Site Number : 8401116
🇺🇸Troy, Michigan, United States
Allergy & Immunology Associates of Ann Arbor- Site Number : 8401078
🇺🇸Ypsilanti, Michigan, United States
SKY Integrative Medical Center/SKYCRNG - Ridgeland- Site Number : 8401058
🇺🇸Ridgeland, Mississippi, United States
Skin Specialists- Site Number : 8401068
🇺🇸Omaha, Nebraska, United States
Jubilee Clinical Research- Site Number : 8401054
🇺🇸Las Vegas, Nevada, United States
Care Access - Hoboken- Site Number : 8401132
🇺🇸Hoboken, New Jersey, United States
Equity Medical- Site Number : 8401239
🇺🇸New York, New York, United States
Icahn School of Medicine at Mount Sinai- Site Number : 8401129
🇺🇸New York, New York, United States
Sadick Research Group - New York - Park Avenue- Site Number : 8401050
🇺🇸New York, New York, United States
OptiSkin- Site Number : 8401163
🇺🇸New York, New York, United States
AXIS Clinicals - Fargo- Site Number : 8401196
🇺🇸Fargo, North Dakota, United States
Bexley Dermatology Research- Site Number : 8401051
🇺🇸Bexley, Ohio, United States
Velocity Clinical Research - Springdale- Site Number : 8401153
🇺🇸Cincinnati, Ohio, United States
Apex Clinical Research Center- Site Number : 8401237
🇺🇸Mayfield Heights, Ohio, United States
Essential Medical Research- Site Number : 8401183
🇺🇸Tulsa, Oklahoma, United States
Oregon Medical Research Center- Site Number : 8401017
🇺🇸Portland, Oregon, United States
Vial Health - DermDox Dermatology- Site Number : 8401031
🇺🇸Camp Hill, Pennsylvania, United States
Paddington Testing Company- Site Number : 8401041
🇺🇸Philadelphia, Pennsylvania, United States
Clinical Research of Philadelphia- Site Number : 8401193
🇺🇸Philadelphia, Pennsylvania, United States
Dermatology Associates of Plymouth Meeting- Site Number : 8401147
🇺🇸Plymouth Meeting, Pennsylvania, United States
Columbia Dermatology & Aesthetics- Site Number : 8401166
🇺🇸Columbia, South Carolina, United States
Tribe Clinical Research - Greenville - ERN - PPDS- Site Number : 8401225
🇺🇸Spartanburg, South Carolina, United States
Health Concepts- Site Number : 8401059
🇺🇸Rapid City, South Dakota, United States
Arlington Research Center- Site Number : 8401248
🇺🇸Arlington, Texas, United States
Dermatology Treatment and Research Center- Site Number : 8401164
🇺🇸Dallas, Texas, United States
Center for Clinical Studies - Houston - Binz Street- Site Number : 8401063
🇺🇸Houston, Texas, United States
Prolato Clinical Research Center- Site Number : 8401209
🇺🇸Houston, Texas, United States
SMS Clinical Research- Site Number : 8401182
🇺🇸Mesquite, Texas, United States
Sienna Dermatology- Site Number : 8401148
🇺🇸Missouri City, Texas, United States
Texas Dermatology and Laser Specialists- Site Number : 8401131
🇺🇸San Antonio, Texas, United States
Stryde Research - Epiphany Dermatology- Site Number : 8401185
🇺🇸Southlake, Texas, United States
Complete Dermatology - Sugar Land- Site Number : 8401061
🇺🇸Sugar Land, Texas, United States
Cope Family Medicine - Ogden Clinic- Site Number : 8401114
🇺🇸Bountiful, Utah, United States
Tanner Clinic - Layton Antelope A- Site Number : 8401151
🇺🇸Layton, Utah, United States
Care Access - Arlington- Site Number : 8401134
🇺🇸Arlington, Virginia, United States
Virginia Dermatology & Skin Cancer Center- Site Number : 8401047
🇺🇸Norfolk, Virginia, United States
Investigational Site Number : 0320021
🇦🇷Berazategui, Buenos Aires, Argentina
Investigational Site Number : 0320019
🇦🇷Caba, Buenos Aires, Argentina
Investigational Site Number : 0320006
🇦🇷Rosario, Santa Fe, Argentina
Investigational Site Number : 0320007
🇦🇷Rosario, Santa Fe, Argentina
Investigational Site Number : 0320011
🇦🇷Buenos Aires, Argentina
Investigational Site Number : 0320015
🇦🇷Rosario, Santa Fe, Argentina
Investigational Site Number : 0320020
🇦🇷San Miguel de Tucumán, Tucumán, Argentina
Investigational Site Number : 0320022
🇦🇷Buenos Aires, Argentina
Investigational Site Number : 0320023
🇦🇷Buenos Aires, Argentina
Investigational Site Number : 0320016
🇦🇷Buenos Aires, Argentina
Investigational Site Number : 0320008
🇦🇷Buenos Aires, Argentina
Investigational Site Number : 0320001
🇦🇷Buenos Aires, Argentina
Investigational Site Number : 0320018
🇦🇷Buenos Aires, Argentina
Investigational Site Number : 0320010
🇦🇷Buenos Aires, Argentina
Investigational Site Number : 0320002
🇦🇷Buenos Aires, Argentina
Investigational Site Number : 0320004
🇦🇷Buenos Aires, Argentina
Investigational Site Number : 0320009
🇦🇷Buenos Aires, Argentina
Investigational Site Number : 0320005
🇦🇷Buenos Aires, Argentina
Investigational Site Number : 0320012
🇦🇷Corrientes, Argentina
Investigational Site Number : 0320013
🇦🇷Mendoza, Argentina
Investigational Site Number : 0360006
🇦🇺Melbourne, Victoria, Australia
Investigational Site Number : 0361006
🇦🇺Traralgon, Victoria, Australia
Centro de Pesquisas da Clínica IBIS- Site Number : 0760002
🇧🇷Salvador, Bahia, Brazil
Investigational Site Number : 1560005
🇨🇳Shanghai, China
Centro de Diagnostico e Pesquisa da Osteoporose do Espirito Santo- Site Number : 0760017
🇧🇷Vitoria, Espírito Santo, Brazil
Hospital São Domingos- Site Number : 0760028
🇧🇷Bequimão, Maranhão, Brazil
PUC Trials- Nucleo de Pesquisa clinica da Escola de Medicina da PUCPR- Site Number : 0760023
🇧🇷Curitiba, Paraná, Brazil
Investigational Site Number : 0360010
🇦🇺Westmead, New South Wales, Australia
Investigational Site Number : 0360007
🇦🇺Woolloongabba, Queensland, Australia
Investigational Site Number : 0360008
🇦🇺Melbourne, Victoria, Australia
Irmandade da Santa Casa de Misericórdia de Porto Alegre- Site Number : 0760005
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760024
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto- Site Number : 0760015
🇧🇷Ribeirão Preto, São Paulo, Brazil
Faculdade de Medicina do ABC- Site Number : 0760001
🇧🇷Santo André, São Paulo, Brazil
Clinica de Alergia Martti Antila- Site Number : 0760006
🇧🇷Sorocaba, São Paulo, Brazil
CCBR / IBPClin - Instituto Brasil de Pesquisa Clínica- Site Number : 0760018
🇧🇷Rio de Janeiro, Brazil
Hospital Alemao Oswaldo Cruz - São Paulo- Site Number : 0760010
🇧🇷São Paulo, Brazil
Centro de Desenvolvimento em Estudos ClÌnicos Brasil- Site Number : 0760014
🇧🇷São Paulo, Brazil
Hospital das Clinicas FMUSP- Site Number : 0760012
🇧🇷São Paulo, Brazil
Investigational Site Number : 1002007
🇧🇬Dupnitsa, Bulgaria
Investigational Site Number : 1002004
🇧🇬Pleven, Bulgaria
Investigational Site Number : 1002005
🇧🇬Sofia, Bulgaria
Investigational Site Number : 1240039
🇨🇦Calgary, Alberta, Canada
Investigational Site Number : 1240031
🇨🇦Edmonton, Alberta, Canada
Investigational Site Number : 1240040
🇨🇦Surrey, British Columbia, Canada
Investigational Site Number : 1240030
🇨🇦Surrey, British Columbia, Canada
Investigational Site Number : 1240041
🇨🇦Winnipeg, Manitoba, Canada
Investigational Site Number : 1240033
🇨🇦Ajax, Ontario, Canada
Investigational Site Number : 1240029
🇨🇦London, Ontario, Canada
Investigational Site Number : 1241106
🇨🇦Markham, Ontario, Canada
Investigational Site Number : 1240008
🇨🇦Mississauga, Ontario, Canada
Investigational Site Number : 1241108
🇨🇦Niagara Falls, Ontario, Canada
Investigational Site Number : 1240034
🇨🇦Ottawa, Ontario, Canada
Investigational Site Number : 1240038
🇨🇦Richmond Hill, Ontario, Canada
Investigational Site Number : 1240012
🇨🇦Toronto, Ontario, Canada
Investigational Site Number : 1240035
🇨🇦Toronto, Ontario, Canada
Investigational Site Number : 1241107
🇨🇦Waterloo, Ontario, Canada
Investigational Site Number : 1240006
🇨🇦Québec City, Quebec, Canada
Investigational Site Number : 1240028
🇨🇦Regina, Saskatchewan, Canada
Investigational Site Number : 1240036
🇨🇦Saskatoon, Saskatchewan, Canada
Investigational Site Number : 1240045
🇨🇦Red Deer, Canada
Investigational Site Number : 1520012
🇨🇱Talcahuano, Biobío, Chile
Investigational Site Number : 1520009
🇨🇱Osorno, Los Lagos, Chile
Investigational Site Number : 1520004
🇨🇱Valdivia, Los Ríos, Chile
Investigational Site Number : 1520013
🇨🇱Santiago, Reg Metropolitana De Santiago, Chile
Investigational Site Number : 1520008
🇨🇱Santiago, Reg Metropolitana De Santiago, Chile
Investigational Site Number : 1520002
🇨🇱Santiago, Reg Metropolitana De Santiago, Chile
Investigational Site Number : 1520003
🇨🇱Santiago, Reg Metropolitana De Santiago, Chile
Investigational Site Number : 1520014
🇨🇱Santiago, Reg Metropolitana De Santiago, Chile
Investigational Site Number : 1520010
🇨🇱Santiago, Reg Metropolitana De Santiago, Chile
Investigational Site Number : 1520011
🇨🇱Santiago, Reg Metropolitana De Santiago, Chile
Investigational Site Number : 1520005
🇨🇱Santiago, Reg Metropolitana De Santiago, Chile
Investigational Site Number : 1520001
🇨🇱Santiago, Reg Metropolitana De Santiago, Chile
Investigational Site Number : 1520015
🇨🇱Quillota, Valparaíso, Chile
Investigational Site Number : 1520006
🇨🇱Viña Del Mar, Valparaíso, Chile
Investigational Site Number : 1560042
🇨🇳Beijing, China
Investigational Site Number : 1560004
🇨🇳Beijing, China
Investigational Site Number : 1560030
🇨🇳Beijing, China
Investigational Site Number : 1560050
🇨🇳Changsha, China
Investigational Site Number : 1560022
🇨🇳Chengdu, China
Investigational Site Number : 1560060
🇨🇳Chengdu, China
Investigational Site Number : 1560068
🇨🇳Chengdu, China
Investigational Site Number : 1560057
🇨🇳Chongqing, China
Investigational Site Number : 1560065
🇨🇳Chongqing, China
Investigational Site Number : 1560043
🇨🇳Fuzhou, China
Investigational Site Number : 1560021
🇨🇳Guangzhou, China
Investigational Site Number : 1560025
🇨🇳Guangzhou, China
Investigational Site Number : 1560058
🇨🇳Guangzhou, China
Investigational Site Number : 1560044
🇨🇳Hangzhou, China
Investigational Site Number : 1560002
🇨🇳Hangzhou, China
Investigational Site Number : 1560006
🇨🇳Hangzhou, China
Investigational Site Number : 1560029
🇨🇳Hangzhou, China
Investigational Site Number : 1560007
🇨🇳Jinan, China
Investigational Site Number : 1560051
🇨🇳Nanchang, China
Investigational Site Number : 1560024
🇨🇳Ningbo, China
Investigational Site Number : 1560001
🇨🇳Shanghai, China
Investigational Site Number : 1560049
🇨🇳Wuhan, China
Investigational Site Number : 1560003
🇨🇳Wuxi, China
Investigational Site Number : 1560028
🇨🇳Zhenjiang, China
Investigational Site Number : 2032106
🇨🇿Kutná Hora, Czechia
Investigational Site Number : 2032105
🇨🇿Nový Jičín, Czechia
Investigational Site Number : 2030010
🇨🇿Olomouc, Czechia
Investigational Site Number : 2032104
🇨🇿Ostrava, Czechia
Investigational Site Number : 2030009
🇨🇿Pilsen, Czechia
Investigational Site Number : 2030008
🇨🇿Prague, Czechia
Investigational Site Number : 2030011
🇨🇿Prague, Czechia
Investigational Site Number : 2030006
🇨🇿Prague, Czechia
Investigational Site Number : 2080002
🇩🇰Aalborg, Denmark
Investigational Site Number : 2080003
🇩🇰Herlev, Denmark
Investigational Site Number : 2500013
🇫🇷Nice, France
Investigational Site Number : 2500007
🇫🇷Reims, France
Investigational Site Number : 2500010
🇫🇷Romans-sur-isère, France
Investigational Site Number : 2500012
🇫🇷Rouen, France
Investigational Site Number : 2500002
🇫🇷Toulouse, France
Investigational Site Number : 2080001
🇩🇰Aarhus, Denmark
Investigational Site Number : 2500008
🇫🇷Antony, France
Investigational Site Number : 2500003
🇫🇷Paris, France
Investigational Site Number : 2500006
🇫🇷Pierre-bénite, France
Investigational Site Number : 2760020
🇩🇪Augsburg, Germany
Investigational Site Number : 2760009
🇩🇪Bad Bentheim, Germany
Investigational Site Number : 2760017
🇩🇪Hamburg, Germany
Investigational Site Number : 2760021
🇩🇪Hamburg, Germany
Investigational Site Number : 2762208
🇩🇪Kiel, Germany
Investigational Site Number : 2760016
🇩🇪Mainz, Germany
Investigational Site Number : 2762201
🇩🇪Münster, Germany
Investigational Site Number : 3000001
🇬🇷Athens, Greece
Investigational Site Number : 3000002
🇬🇷Thessaloniki, Greece
Investigational Site Number : 3560001
🇮🇳Ahmedabad, India
Investigational Site Number : 3560005
🇮🇳Belagavi, India
Investigational Site Number : 3560004
🇮🇳Chandigarh, India
Investigational Site Number : 3560006
🇮🇳Haryana, India
Investigational Site Number : 3560007
🇮🇳Kolkata, India
Investigational Site Number : 3560002
🇮🇳Nagpur, India
Investigational Site Number : 3560003
🇮🇳Pune, India
Investigational Site Number : 3760004
🇮🇱Afula, Israel
Investigational Site Number : 3760005
🇮🇱Be'er Sheva, Israel
Investigational Site Number : 3760001
🇮🇱Haifa, Israel
Investigational Site Number : 3760003
🇮🇱Jerusalem, Israel
Investigational Site Number : 3760006
🇮🇱Petah Tikva, Israel
Investigational Site Number : 3760002
🇮🇱Petah Tikva, Israel
Investigational Site Number : 3800003
🇮🇹Milan, Milano, Italy
Investigational Site Number : 3800018
🇮🇹Rozzano, Milano, Italy
Investigational Site Number : 3800013
🇮🇹Rome, Roma, Italy
Investigational Site Number : 3800009
🇮🇹Catania, Italy
Investigational Site Number : 3800011
🇮🇹L'aquila, Italy
Investigational Site Number : 3800008
🇮🇹Pisa, Italy
Investigational Site Number : 3920009
🇯🇵Chitose, Hokkaido, Japan
Investigational Site Number : 3923114
🇯🇵Obihiro, Hokkaido, Japan
Investigational Site Number : 3920008
🇯🇵Sapporo, Hokkaido, Japan
Investigational Site Number : 3920006
🇯🇵Kobe, Hyogo, Japan
Investigational Site Number : 3920005
🇯🇵Sagamihara, Kanagawa, Japan
Investigational Site Number : 3923113
🇯🇵Yokohama, Kanagawa, Japan
Investigational Site Number : 3920010
🇯🇵Miyagi-gun, Miyagi, Japan
Investigational Site Number : 3920011
🇯🇵Sendai, Miyagi, Japan
Investigational Site Number : 3923109
🇯🇵Habikino, Osaka, Japan
Investigational Site Number : 3923110
🇯🇵Sakai, Osaka, Japan
Investigational Site Number : 3920002
🇯🇵Iruma, Saitama, Japan
Investigational Site Number : 3923106
🇯🇵Mibu, Tochigi, Japan
Investigational Site Number : 3920004
🇯🇵Chuo, Tokyo, Japan
Investigational Site Number : 3923107
🇯🇵Minato, Tokyo, Japan
Investigational Site Number : 3920001
🇯🇵Tachikawa, Tokyo, Japan
Investigational Site Number : 3923108
🇯🇵Kagoshima, Japan
Investigational Site Number : 3923102
🇯🇵Kyoto, Japan
Investigational Site Number : 3920003
🇯🇵Kyoto, Japan
Investigational Site Number : 4100008
🇰🇷Daegu, Daegu-gwangyeoksi, Korea, Republic of
Investigational Site Number : 4100012
🇰🇷Gwangju, Gwangju-gwangyeoksi, Korea, Republic of
Investigational Site Number : 4100002
🇰🇷Ansan-si, Gyeonggi-do, Korea, Republic of
Investigational Site Number : 4100014
🇰🇷Seongnam, Gyeonggi-do, Korea, Republic of
Investigational Site Number : 4100009
🇰🇷Suwon-si, Gyeonggi-do, Korea, Republic of
Investigational Site Number : 4100003
🇰🇷Yangsan-si, Gyeongsangnam-do, Korea, Republic of
Investigational Site Number : 4100015
🇰🇷Bupyeong-gu, Incheon-gwangyeoksi, Korea, Republic of
Investigational Site Number : 4100010
🇰🇷Seoul, Seoul-teukbyeolsi, Korea, Republic of
Investigational Site Number : 4100013
🇰🇷Seoul, Seoul-teukbyeolsi, Korea, Republic of
Investigational Site Number : 4100007
🇰🇷Seoul, Seoul-teukbyeolsi, Korea, Republic of
Investigational Site Number : 4100006
🇰🇷Seoul, Seoul-teukbyeolsi, Korea, Republic of
Investigational Site Number : 4100011
🇰🇷Seoul, Seoul-teukbyeolsi, Korea, Republic of
Investigational Site Number : 4100017
🇰🇷Seoul, Seoul-teukbyeolsi, Korea, Republic of
Investigational Site Number : 4840005
🇲🇽Monterrey, Nuevo León, Mexico
Investigational Site Number : 4840012
🇲🇽Aguascalientes, Mexico
Investigational Site Number : 4840009
🇲🇽Durango, Mexico
Investigational Site Number : 4840003
🇲🇽Veracruz, Mexico
Investigational Site Number : 6160004
🇵🇱Lublin, Lubelskie, Poland
Investigational Site Number : 6160002
🇵🇱Lodz, Lódzkie, Poland
Investigational Site Number : 6162406
🇵🇱Krakow, Malopolskie, Poland
Investigational Site Number : 6160010
🇵🇱Tarnow, Malopolskie, Poland
Investigational Site Number : 6160009
🇵🇱Warsaw, Mazowieckie, Poland
Investigational Site Number : 6160007
🇵🇱Warsaw, Mazowieckie, Poland
Investigational Site Number : 6160003
🇵🇱Katowice, Slaskie, Poland
Investigational Site Number : 6200005
🇵🇹Lisbon, Portugal
Investigational Site Number : 6200004
🇵🇹Lisbon, Portugal
Investigational Site Number : 6200001
🇵🇹Lisbon, Portugal
Investigational Site Number : 6200003
🇵🇹Porto, Portugal
Investigational Site Number : 7100015
🇿🇦Benoni, South Africa
Investigational Site Number : 7100010
🇿🇦Cape Town, South Africa
Investigational Site Number : 7100009
🇿🇦Cape Town, South Africa
Investigational Site Number : 7100012
🇿🇦Durban, South Africa
Investigational Site Number : 7100001
🇿🇦Durban, South Africa
Investigational Site Number : 7100007
🇿🇦Johannesburg, South Africa
Investigational Site Number : 7100003
🇿🇦Pretoria, South Africa
Investigational Site Number : 7240012
🇪🇸Las Palmas de Gran Canaria, Las Palmas, Spain
Investigational Site Number : 7240015
🇪🇸Pamplona, Navarra, Spain
Investigational Site Number : 7240008
🇪🇸Bilbao, Pais Vasco, Spain
Investigational Site Number : 7240014
🇪🇸Vigo, Pontevedra [Pontevedra], Spain
Investigational Site Number : 7240020
🇪🇸Seville, Sevilla, Spain
Investigational Site Number : 1583202
🇨🇳Taichung, Taiwan
Investigational Site Number : 7240023
🇪🇸Burjassot, Valencia, Spain
Investigational Site Number : 1583201
🇨🇳Kaohsiung City, Taiwan
Investigational Site Number : 7242505
🇪🇸Alicante, Spain
Investigational Site Number : 7240018
🇪🇸Granada, Spain
Investigational Site Number : 7242503
🇪🇸Madrid, Spain
Investigational Site Number : 7240019
🇪🇸Granada, Spain
Investigational Site Number : 1580001
🇨🇳Taipei City, Taiwan
Investigational Site Number : 7520006
🇸🇪Alvsjo, Sweden
Investigational Site Number : 7520001
🇸🇪Orebro, Sweden
Investigational Site Number : 1580003
🇨🇳Taipei, Taiwan
Investigational Site Number : 7920001
🇹🇷Antalya, Turkey
Investigational Site Number : 7920008
🇹🇷Gaziantep, Turkey
Investigational Site Number : 7920005
🇹🇷Istanbul, Turkey
Investigational Site Number : 7920009
🇹🇷Istanbul, Turkey
Investigational Site Number : 7920004
🇹🇷Kayseri, Turkey
Investigational Site Number : 7920007
🇹🇷Samsun, Turkey
Investigational Site Number : 8260003
🇬🇧Portsmouth, Hampshire, United Kingdom
Investigational Site Number : 8262601
🇬🇧London, London, City Of, United Kingdom
Investigational Site Number : 8262602
🇬🇧London, London, City Of, United Kingdom
Investigational Site Number : 8260006
🇬🇧Glasgow, United Kingdom
Investigational Site Number : 8260004
🇬🇧Leicester, United Kingdom